Literature DB >> 21362314

Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor.

Qi-Ming Dai1, Jing Lu, Nai-Feng Liu.   

Abstract

BACKGROUND: Diabetic myocardiopathy is characterized by myocardial interstitial fibrosis and cardiac dysfunction. Statins were found to exert protective effects on cardiovascular disease by suppressing activation of small G proteins, independently of their lipid-lowering effect. The study investigated the effect of fluvastatin on myocardial interstitial fibrosis, cardiac function and mechanism of its action in diabetic rats.
METHODS: Twenty-four male SD rats were randomly assigned to 3 groups: control rats (n = 8), streptozotocin (STZ)-induced diabetic rats (n = 8), and diabetic rats treated with fluvastatin (administered fluvastatin orally, 10 mg/kg body weight per day, n = 8). Twelve weeks later, miniature cardiac catheter was inserted into the left ventricle to conduct hemodynamic examination. Then myocardium tissues were collected, collagen content was detected by picro-sirius red staining, real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of connective tissue growth factor (CTGF), and Western blotting was used to detect the protein expression of CTGF. Rho activity was determined by pull-down assay.
RESULTS: After 12 weeks, the left ventricular systolic pressure (LVSP) and maximum rate of left ventricular (LV) pressure rise and fall (+dP/dt max and -dP/dt max) were significantly lower and left ventricular end diastolic pressure (LVEDP) was higher in the diabetic rats than those in the control rats (P < 0.01). Moreover, in LV myocardial tissue of diabetic rats the collagen content, fibronectin, mRNA and protein expression of CTGF and the activity of RhoA were all significantly increased compared with the control rats (P < 0.01). Administration of fluvastain obviously improved the cardiac function of diabetic rats, attenuated fibronectin expression, mRNA and protein expression of CTGF and the activity of RhoA in LV myocardium of diabetic rats.
CONCLUSIONS: Fluvastatin attenuates cardiac dysfunction and myocardial interstitial fibrosis of diabetic rat by inhibiting activity of RhoA to down-regulate the overexpression of CTGF, and Rho/Rho-kinase pathway may be an important target in the treatment of diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21362314

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  11 in total

1.  Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress.

Authors:  Ahmed A M Abdel-Hamid; Alaa El-Din L Firgany
Journal:  J Mol Histol       Date:  2015-06-04       Impact factor: 2.611

Review 2.  CSI position statement on management of heart failure in India.

Authors:  Santanu Guha; S Harikrishnan; Saumitra Ray; Rishi Sethi; S Ramakrishnan; Suvro Banerjee; V K Bahl; K C Goswami; Amal Kumar Banerjee; S Shanmugasundaram; P G Kerkar; Sandeep Seth; Rakesh Yadav; Aditya Kapoor; Ajaykumar U Mahajan; P P Mohanan; Sundeep Mishra; P K Deb; C Narasimhan; A K Pancholia; Ajay Sinha; Akshyaya Pradhan; R Alagesan; Ambuj Roy; Amit Vora; Anita Saxena; Arup Dasbiswas; B C Srinivas; B P Chattopadhyay; B P Singh; J Balachandar; K R Balakrishnan; Brian Pinto; C N Manjunath; Charan P Lanjewar; Dharmendra Jain; Dipak Sarma; G Justin Paul; Geevar A Zachariah; H K Chopra; I B Vijayalakshmi; J A Tharakan; J J Dalal; J P S Sawhney; Jayanta Saha; Johann Christopher; K K Talwar; K Sarat Chandra; K Venugopal; Kajal Ganguly; M S Hiremath; Milind Hot; Mrinal Kanti Das; Neil Bardolui; Niteen V Deshpande; O P Yadava; Prashant Bhardwaj; Pravesh Vishwakarma; Rajeeve Kumar Rajput; Rakesh Gupta; S Somasundaram; S N Routray; S S Iyengar; G Sanjay; Satyendra Tewari; Sengottuvelu G; Soumitra Kumar; Soura Mookerjee; Tiny Nair; Trinath Mishra; U C Samal; U Kaul; V K Chopra; V S Narain; Vimal Raj; Yash Lokhandwala
Journal:  Indian Heart J       Date:  2018-06-08

3.  The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts.

Authors:  Young Hee Shin; Jeong Jin Min; Jong-Hwan Lee; Eun-Hee Kim; Go Eun Kim; Myung Hee Kim; Jeong Jin Lee; Hyun Joo Ahn
Journal:  Heart Vessels       Date:  2016-12-24       Impact factor: 2.037

Review 4.  Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management.

Authors:  Joseph M Pappachan; George I Varughese; Rajagopalan Sriraman; Ganesan Arunagirinathan
Journal:  World J Diabetes       Date:  2013-10-15

Review 5.  Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart.

Authors:  Raphael M Singh; Tahreem Waqar; Frank C Howarth; Ernest Adeghate; Keshore Bidasee; Jaipaul Singh
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

6.  Urocortin ameliorates diabetic cardiomyopathy in rats via the Akt/GSK-3β signaling pathway.

Authors:  Xinyu Liu; Chunna Liu; Xiaoyan Zhang; Jiajun Zhao; Jin Xu
Journal:  Exp Ther Med       Date:  2015-01-23       Impact factor: 2.447

7.  Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats.

Authors:  Nawal M Al-Rasheed; Nouf M Al-Rasheed; Iman H Hasan; Maha A Al-Amin; Hanaa N Al-Ajmi; Raeesa A Mohamad; Ayman M Mahmoud
Journal:  Oxid Med Cell Longev       Date:  2017-09-12       Impact factor: 6.543

8.  Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control.

Authors:  Jeong Jin Min; Byung-Seop Shin; Jong-Hwan Lee; Yunseok Jeon; Dae Kyun Ryu; Sojin Kim; Young Hee Shin
Journal:  J Diabetes Res       Date:  2018-02-28       Impact factor: 4.011

9.  Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpression.

Authors:  Olaf Brouwers; Joyce M J de Vos-Houben; Petra M G Niessen; Toshio Miyata; Frans van Nieuwenhoven; Ben J A Janssen; Geja Hageman; Coen D A Stehouwer; Casper G Schalkwijk
Journal:  Int J Mol Sci       Date:  2013-07-29       Impact factor: 5.923

10.  Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy.

Authors:  Aude Carillion; Sarah Feldman; Na Na; Matthieu Biais; Wassila Carpentier; Aurélie Birenbaum; Nicolas Cagnard; Xavier Loyer; Dominique Bonnefont-Rousselot; Stéphane Hatem; Bruno Riou; Julien Amour
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.